GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Quantrx Biomedical Corp (OTCPK:QTXB) » Definitions » Financial Strength

Quantrx Biomedical (Quantrx Biomedical) Financial Strength : 0 (As of Sep. 2022)


View and export this data going back to . Start your Free Trial

What is Quantrx Biomedical Financial Strength?

Quantrx Biomedical has the Financial Strength Rank of 0.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

Quantrx Biomedical did not have earnings to cover the interest expense. As of today, Quantrx Biomedical's Altman Z-Score is 0.00.


Competitive Comparison of Quantrx Biomedical's Financial Strength

For the Medical Instruments & Supplies subindustry, Quantrx Biomedical's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Quantrx Biomedical's Financial Strength Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Quantrx Biomedical's Financial Strength distribution charts can be found below:

* The bar in red indicates where Quantrx Biomedical's Financial Strength falls into.



Quantrx Biomedical Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Quantrx Biomedical's Interest Expense for the months ended in Sep. 2022 was $-0.05 Mil. Its Operating Income for the months ended in Sep. 2022 was $-0.01 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was $0.00 Mil.

Quantrx Biomedical's Interest Coverage for the quarter that ended in Sep. 2022 is

Quantrx Biomedical did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

Quantrx Biomedical's Debt to Revenue Ratio for the quarter that ended in Sep. 2022 is

Debt to Revenue Ratio=Total Debt (Q: Sep. 2022 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(2.829 + 0) / 0
=N/A

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Quantrx Biomedical has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Quantrx Biomedical  (OTCPK:QTXB) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

Quantrx Biomedical has the Financial Strength Rank of 0.


Quantrx Biomedical Financial Strength Related Terms

Thank you for viewing the detailed overview of Quantrx Biomedical's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Quantrx Biomedical (Quantrx Biomedical) Business Description

Traded in Other Exchanges
N/A
Address
10190 SW 90th Avenue, Tualatin, OR, USA, 97062
Quantrx Biomedical Corp operates towards the development and commercialization of patented mini form pad (PAD) based products. The PAD products are based on the company's non-woven disposable absorbent pad technology and it is involved in the PAD-based over-the-counter products for the treatment of hemorrhoids, minor vaginal infection, urinary incontinence, general catamenial uses, and other medical needs. Its platforms include inSync(R), Unique(TM), and OEM branded over-the-counter and laboratory testing products.
Executives
Michael S Abrams director 64 RAMSHEAD ROAD, RAYNHAM MA 02767
Patrick T Mooney director C/O SONTRA MEDICAL CORPORATION, 10 FORGE PARKWAY, FRANKLIN MA 02038
Robert G. Pinco director 1700 K STREET NW, SUITE 300, WASHINGTON DC 20006
Hayes Arthur H Jr director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Matthew Balk 10 percent owner 229 WEST 60TH STREET, NEW YORK NY 10023
Evan Levine director, 10 percent owner 1517 SAN JACINTO ST., HOUSTON TX 77002
Hayes Arthur Hull Jr director C/O QUANTRX BIOMEDICAL CORPORATION, 100 S. MAIN STREET, SUITE 300, DOYLESTOWN PA 18901
Cindy Horton officer: V.P. of Diagnostics 209 BRITTANY PARK, ANDERSON SC 29621
Sasha Afanassiev officer: Officer 120 GARRISON COURT, LANGHORNE PA 19047
Shalom Hirschman officer: Officer 5240 BLACKSTONE AVENUE, RIVERDALE NY 10471
William H Fleming director, officer: Secretary
Walter W Witoshkin director, officer: President and CEO 321 NORRISTOWN ROAD, SUITE 230, AMBLE PA 19002
Mark Capital Llc 10 percent owner 5173 SEAGROVE PLACE, SAN DIEGO CA 92130
Sherbrooke Partners, Llc 10 percent owner 570 LEXINGTON AVENUE, FLOOR 3, NEW YORK NY 10022
Goldman Sachs & Co. Llc 10 percent owner 200 WEST STREET, NEW YORK NY 10282

Quantrx Biomedical (Quantrx Biomedical) Headlines

No Headlines